Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

Shares in the pharmaceutical company fell a staggering 85% on Monday after it reported disappointing Phase 3 results, but its ...

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) ...

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

On Tuesday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $3.83 which represents a decrease of $-0.47 or -10.93% from the prior close of $4.3. The stock opened at $4.32 and ...

Cassava Sciences ( SAVA) stock dropped 87% on Monday to close the day’s trading at $4.29 a shares. Cassava is a biotechnology ...

Wall Street witnessed a historic day with the S&P 500 and Dow Jones Industrial Average reaching record highs. The Russell ...

Cassava Sciences Inc.’s stock crated 85% in premarket trade Monday, after the clinical-stage biotech said a trial of a treatment for mild-to-moderate Alzheimer’s disease failed to meet its main goals.

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s ...